Biocon Biologics Moves into New North American Headquarters in Bridgewater, New Jersey

Tue, 16 Jul 2024
Posted by: Biocon Biologics
Download Press Release

BRIDGEWATER, New Jersey, July 16, 2024 

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company, today announced that the company has established its first North American headquarters in Bridgewater, New Jersey. This brings the company into a new 9,624-square-foot (sf) office located at 685 Route 202/206 within the state’s biopharma corridor. The new headquarters will house both commercial and administrative functions for the organization.

Josh Salsi, Head of North America, Biocon Biologics, said: “We are excited to establish our first North America headquarters within the hub of the biopharma sector of New Jersey where we can leverage the strong life sciences ecosystem of innovation, talent, and excellent quality of life for our employees and be well-positioned for future growth.”

Biocon Limited, the parent company of Biocon Biologics, operates a manufacturing facility in Cranbury as well as an office in Iselin, New Jersey.

About Biocon Biologics Limited:

Biocon Biologics Ltd. (BBL), a subsidiary of Biocon Ltd., is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives by enabling affordable access to high quality biosimilars for millions of patients worldwide. It is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes.

BBL has integrated the acquired global biosimilars business of its long-standing partner Viatris, which is a historic milestone in its value creation journey. Biocon Biologics has commercialized eight biosimilars in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. The Company has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. It has many ‘firsts’ to its credit in the biosimilars industry. As part of its environmental, social and governance (ESG) commitment, BBL is advancing the health of patients, people, and the planet to achieve key UN Sustainable Development Goals (SDGs). Website: www.bioconbiologics.com; Follow us on Twitter: @BioconBiologics and LinkedIn: Biocon Biologics for company updates.

Author:
Biocon Biologics

You are now leaving Biocon Biologics U.S., a Biocon Biologics website. The website you are about to access is not owned or controlled by Biocon Biologics Inc.

Biocon Biologics Inc. assumes no responsibility for and makes no warranties or representations of any kind as to the accuracy, currency, or completeness of any information contained in such third-party website, including any third-party social media or mobile application platform. Inclusion of any third-party link on this website does not imply an endorsement or recommendation by Biocon Biologics, and a link to this website from another website does not imply a relationship between Biocon Biologics and any third party. Your use of any such third-party site or platform is at your own risk and will be governed by such third party’s terms and policies (including its privacy policy). Biocon Biologics shall not be liable for any direct, indirect, consequential, incidental, or punitive damages arising out of access to, use of, or inability to use such third-party website, or any errors or omissions in the content thereof.

OK
CANCEL

You are now departing from the Biocon Biologics U.S. website and redirected to the Biocon Biologics corporate website. Please be aware that the Biocon Biologics corporate website may contain information that varies from the content on the Biocon Biologics U.S. website. The website you are about to access is the corporate website located outside of U.S.
U.S. regulations may not be applicable to the content on this corporate website.

OK
CANCEL